Warner–Lambert

Goodes Prize Luncheon 2015

• Report rights infringement
• published: 02 Nov 2015
• views: 228

The Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery honors an innovative researcher who has made a significant and lasting impact in the field. Drug discovery researchers are often under recognized and make critical contributions toward the development of effective treatments and a cure for Alzheimer’s disease. This prize recognizes their determined efforts. It is named for Melvin Goodes, a distinguished leader in the pharmaceutical industry, who brought about drug breakthroughs that improved millions of lives. The inaugural Goodes Prize winner will be announced at a private ceremony on September 29, 2015. As a leader in supporting the most promising Alzheimer’s drug discovery research worldwide, the ADDF is proud to present the Goodes Prize to those men and women who have dedicated their careers to finding a cure for this devastating disease. It includes a grant of $150,000 to support the winner’s future research in Alzheimer’s drug discovery. The 2015 Selection Committee includes leaders in Alzheimer’s research and drug discovery. The Committee nominates a select group for consideration. Top nominees are asked to submit an application that includes a biography, summary of past work, and a description of innovative research in need of funding. The Selection Committee chooses the winner from this pool of nominees. (Individuals on the Selection Committee are not eligible to receive the award.) To be eligible, nominees must: Be a professionally active (i.e., not retired) investigator with an interdisciplinary research career whose work reflects a lifelong commitment to Alzheimer's drug discovery and development. Nominees can be a medicinal chemist, pharmacologist, clinical trialist, or neurobiology researcher who embodies a spirit of entrepreneurship and has a history of producing ground-breaking research. Be recognized by their peers as a leader and innovator in the field of Alzheimer’s drug discovery and development. Have published results related to Alzheimer’s and related dementia drug discovery research in significant and peer-reviewed journals and/or as patent applications. Be affiliated with a major academic research/medical center, government, industry, and/or non-profit organization(s). The 2015 Selection Committee Howard M. Fillit, MD, Alzheimer’s Drug Discovery Foundation Elias Michaelis, MD, PhD, University of Kansas Richard Mohs, PhD, Eli Lilly Suzana Petanceska, PhD, National Institute on Aging Rachel Schindler, MD, Pfizer Linda Van Eldik, PhD, University of Kentucky About Melvin R. Goodes Melvin R. Goodes joined Warner-Lambert Canada as manager of new product development in 1965 and quickly rose through the ranks to become CEO and Chairman Worldwide in 1991. Under his leadership, Warner-Lambert became a major player in the prescription drug industry, bringing Lipitor to market in 1996. Lipitor, a highly effective statin, was the world’s best-selling drug, with more than $125 billion in sales. Mr. Goodes earned his bachelors of commerce degree and was granted an honorary doctorate of laws from Queen’s University in Kingston, Ontario. He earned a master’s of business administration from the University of Chicago Booth School of Business in 1960, where he was a Ford Foundation and Sears Roebuck fellow. In 2010, Mr. Goodes made headlines with a landmark speech revealing his early-stage Alzheimer’s disease and pledging his all to speed up the search for new therapies. Since this speech, he and his wife Nancy have traveled the nation as advocates for the ADDF, inspiring hope among Alzheimer’s patients, caregivers, physicians and researchers. Both Mr. Goodes and his wife are members of the ADDF’s Board of Governors.